Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

Winton, Timothy; Livingston, Robert B.; Johnson, David C.; Rigas, James R.; Johnston, Michael; Butts, Charles; Cormier, Yvon; Goss, Glenwood; Inculet, Richard; Vallières, Eric; Fry, Willard A.; Bethune, Drew; Ayoub, Joseph; Ding, Keyue; Seymour, Lesley; Graham, Barbara; Tsao, Ming‐Sound; Gandara, David R.; Kesler, Kenneth A.; Demmy, Todd L.; Shepherd, Frances A.

doi:10.1056/nejmoa043623

articleNew England Journal of MedicineJun 22, 2005BRONZE OA

Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

TWTimothy Winton RBRobert B. Livingston DCDavid C. Johnson JRJames R. Rigas MJMichael Johnston

Ontario Institute for Cancer Research · SWOG Cancer Research Network · +2 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer.

Methods

We randomly assigned patients with completely resected stage IB or stage II non-small-cell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen.

Citation impact

1,829

total citations

FWCI: 103.61
Percentile: 100%
References: 36

Citations per year

Authors

21

Topics & keywords

Topics

Keywords

Medicine
Vinorelbine
Internal medicine
Neutropenia
Lung cancer
Gastroenterology
Surgery
Hazard ratio

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.